Trial Profile
A Phase II, Randomised, Open-Label, Multicentre Study of AS1402 in Combination With Letrozole as First Line Treatment in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs BTH 1704 (Primary) ; Letrozole
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- 15 Mar 2012 This trial has been recruiting in France and discontinued in Poland as reported by European Clinical Trials Database record.
- 21 Nov 2009 Status changed from discontinued to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 12 Aug 2009 Additional lead trial investigator Acton G identified as reported by ClinicalTrials.gov.